Dear Friends,
Due to the recent hurricane we are going to postpone tomorrow's MD STARnet webinar.
We will be in touch regarding the new date. Sorry for the inconvenience.
Best,
Ryan Fischer
PPMD
Added by PPMD on October 30, 2012 at 1:00pm — No Comments
Background
Friends, we have been actively pursuing a regulatory strategy and have had two meetings with the neurology division at the FDA. We are currently working on the 'to do' list for the community and are trying to understand barriers/obstacles to approval from the FDA side, as well as, from the sponsor side of the issue. We are working a smart, targeted call to action. We have learned through years…
ContinueAdded by Pat Furlong on October 23, 2012 at 11:30pm — 6 Comments
New release from Prosensa:
£10m in milestone payments received from GlaxoSmithKline
Leiden, The Netherlands, 23 October 2012 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted…
ContinueAdded by PPMD on October 23, 2012 at 12:35pm — 2 Comments
1997 may not seem so long ago, but at times it feels like half a lifetime to me. That was the year my family learned Matthew’s motor difficulties were something physical therapy could not correct and the first time we heard the word Duchenne. Everyone’s world changes after diagnosis of a devastating chronic illness and over the years my family and I experienced many…
Added by Brian Denger on October 22, 2012 at 8:00am — 3 Comments
Dr. Jerry Mendell, Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb eteplirsen study, presented the full set of 48-week data from…
Added by PPMD on October 16, 2012 at 9:00am — No Comments
In the clinical trial world, there are some things that divide us these days- most specifically, what mutation type your son has. However, we are united in wanting better ways to look for the benefits of potential drugs; who isn’t hoping for a day when the muscle biopsy is a relic from the past?
There are several dedicated research teams doing exciting work…
ContinueAdded by Holly Peay on October 13, 2012 at 10:00am — No Comments
In light of PPMD’s Cardiac Webinar Series, our Director of Care, Kathi Kinnett answers questions/concerns about Ventricular Assist Devices (VAD).
There has been recent discussion worldwide…
Added by Kathi Kinnett on October 11, 2012 at 2:30pm — No Comments
These are the words that best describe PPMD’s research plan.
Everything we do goes through this filter to make sure that we are achieving one of these…
ContinueAdded by Sharon Hesterlee on October 11, 2012 at 11:00am — 4 Comments
Following closely on the heels of the good news about Sarepta’s exon 51 skipping strategy, PPMD is pleased to report that Summit…
Added by Sharon Hesterlee on October 10, 2012 at 10:30am — 13 Comments
With the recent news of Sarepta's promising 48-week data, many have asked how accelerated approval may play into the FDA review of eteplirsen. Let's first define what accelerated approval means.
Because it…
ContinueAdded by Ryan Fischer on October 5, 2012 at 2:00pm — 1 Comment
The much-anticipated 48-week results on eteplirsen, a drug designed to skip exon 51, were presented today by Sarepta Therapeutics on a webinar and press release. On the webinar, Sarepta’s Chief Executive Chris Garabedian presented data about the dystrophin found in study participants’ muscle biopsies and the…
Added by Holly Peay on October 3, 2012 at 4:00pm — 5 Comments
Jeans. Genes. Thursday night, I changed from jeans into a blue dress – as in blue jean blue. The recommended color for the R.A.R.E. Gala. The focus was genes, rare genetic disorders. While most of my days are focused on Duchenne, I am very aware that Duchenne is 1 of 7,000 rare…
Added by Pat Furlong on October 1, 2012 at 3:00pm — No Comments
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service